Drug Trial Radar · NCT03036124
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
Last checked: Nov 19, 2026Latest source record: Sep 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,744
Actual
Start
Feb 8, 2017
Primary completion
Jul 17, 2019
Study completion Jul 17, 2019
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
DapagliflozinDrug
10 mg or 5 mg tablets given once daily, per oral use.
PlaceboDrug
Placebo matching dapagliflozin 10 mg or 5 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.Time frame: Up to 27.8 months.
Locations
419 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
Fairhope, Alabama
Research Site
Mobile, Alabama
Research Site
Sheffield, Alabama
Research Site
Bakersfield, California
Research Site
Beverly Hills, California
Research Site
Los Angeles, California
Research Site
Palm Springs, California
Research Site
Stockton, California
Research Site
Torrance, California
Research Site
Vista, California
Research Site
Wilmington, Delaware
Research Site
Boynton Beach, Florida
Research Site
Jacksonville, Florida
Research Site
Jacksonville, Florida
Research Site
Lake Worth, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Naples, Florida
Research Site
New Smyrna Beach, Florida
Research Site
Pembroke Pines, Florida
Research Site
Port Charlotte, Florida
Research Site
Saint Augustine, Florida
Research Site
Wellington, Florida
Research Site
Atlanta, Georgia
Research Site
Cumming, Georgia
Research Site
Tucker, Georgia
Research Site
Hazel Crest, Illinois
Research Site
Jerseyville, Illinois
Research Site
Peoria, Illinois
Research Site
Louisville, Kentucky
Research Site
Alexandria, Louisiana
Research Site
Chalmette, Louisiana
Research Site
Bangor, Maine
Research Site
Baltimore, Maryland
Research Site
Baltimore, Maryland
Research Site
Columbia, Maryland
Research Site
Boston, Massachusetts
Research Site
Haverhill, Massachusetts
Research Site
Flint, Michigan
Research Site
Flint, Michigan
Showing 40 of 419 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.